Vedolizumab
0
0
Mo1561 GUT SELECTIVE BIOLOGIC, VEDOLIZUMAB, IS ASSOCIATED WITH LOWER RATES OF LIVER RELATED COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH ...
reviewer4you.com
0
0
Su1848 OUTCOMES FOLLOWING ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE THERAPIES TO VEDOLIZUMAB OR USTEKINUMAB
0
0
Peyrin‐Biroulet, L., Arkkila, P., Armuzzi, A. et al. BMC Gastroenterol 24, 121 (2024). https://doi.org/10.1186/s12876-024-03163-5. Open Access! ...
0
0
April 10, 2024 2 min read ...
0
0
Background: Pregnancy outcomes in patients with inflammatory bowel disease with quiescent disease are similar to those in the general ...